Affiliations 

  • 1 School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor Malaysia
  • 2 Department of Pharmacy, School of Science, Kathmandu University, Dhulikhel, Kavre Nepal
  • 3 Department of Pharmaceutical and Health Service Research, Nepal Health Research and Innovation Foundation, Lalitpur, Nepal
  • 4 Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
  • 5 School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
  • 6 Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom
  • 7 Grupo de Investigación Biomedicina, Faculty of Medicine, Fundacion Universitaria Autonoma de Las Americas, Pereira, Risaralda Colombia
Drugs Ther Perspect, 2021;37(8):376-382.
PMID: 34366660 DOI: 10.1007/s40267-021-00852-z

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.